In the past, many viral gene delivery agents were unsuitable for clinical applications due to their high immunogenicity and propensity to cause cancer. To bring gene therapy to the clinic, scientists ...

Focused specifically on examining gene therapy immunogenicity, this event will enable you to learn how to evaluate and overcome pre-existing immunity to AAV vectors, understand how immune ...

These properties, together with a favorable toxicity profile and minimal immunogenicity, indicate that AAV is likely to be a suitable vector for gene therapy applications which require sustained ...

Establishing how AAV-mediated immunogenicity in the retina triggers acute and persistent inflammation is critical to developing approaches to avoid this sight threatening complication of treatment.

They can infect both dividing and non-dividing cells and provide long-term gene expression. AAV vectors have a low immunogenicity profile, making them attractive for gene therapy applications.

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research ...

INS1201 represents the first application of Insmed’s targeted adeno-associated virus (AAV) delivery platform in DMD ... which ...